A phase II, multi-center, open label study of melphalan, prednisone, thalidomide and bortezomib [Velcade] in advanced and refractory multiple myeloma patients
Latest Information Update: 02 Jun 2011
Price :
$35 *
At a glance
- Drugs Bortezomib (Primary) ; Melphalan (Primary) ; Prednisone (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 03 Nov 2006 New trial record.